Skip to main content
Clinical Trials/NCT01979289
NCT01979289
Unknown
Not Applicable

Computerized Cognitive Remediation for Geriatric Depression

Weill Medical College of Cornell University1 site in 1 country60 target enrollmentAugust 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Weill Medical College of Cornell University
Enrollment
60
Locations
1
Primary Endpoint
Montgomery-Asberg Depression Rating Scale
Last Updated
9 years ago

Overview

Brief Summary

This research study will examine if a targeted computerized cognitive remediation (CCR) training program is better for treating geriatric depression than general computer activity. We will also examine whether this intervention is related to improvement in cognitive and depressive symptoms. Elderly patients with depression, who have, and who have not been treated with antidepressant medication for their illness, will be recruited to participate in either a 30 hour cognitive remediation program or general computer activity designed to be both challenging and interesting. They will be asked to complete between 1 and 3 hours of remediation per day over 4 weeks. While undergoing the cognitive remediation participants will be asked questions to assess their symptoms of, as well as the severity of, their depression weekly. This will inform researchers about whether or not the CCR is helping to improve depressive symptoms. At the end of the CCR study, participants will be given a battery of cognitive tests design to tell investigators whether or not the CCR improved their thinking in a variety of different ways including improving attention, memory, and organization. Investigators will also determine whether changes in participants' thinking are related to changes in their mood or other depressive symptoms. It is hoped that information gained from this study will help investigators to better understand the brain processes associated with depression, recovery from depression, and will help inform the development of future alternative treatments for this illness.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
July 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Medicated Depressed Participants' Inclusion Criteria
  • Age: 60-89 years
  • Diagnosis: Major depression, unipolar (by DSM-IV criteria);
  • Severity of depression: MADRS \>or =15 following at least 8-weeks of controlled antidepressant treatment.
  • No plans to change current antidepressant treatment.
  • Non-Medicated Depressed Participants' Inclusion Criteria
  • Age: 60-89 years
  • Diagnosis: Major depression, unipolar (by DSM-IV criteria);
  • Severity of depression: MADRS \>or =15
  • No antidepressant treatment within the current episode. -

Exclusion Criteria

  • Psychotic depression by DSM-IV, i.e., presence of delusions with a score higher than 2 (questionable delusion) rated by the Scale for Assessment of Positive Symptoms (SAPS) \[47\];
  • High suicide risk, i.e. intent or plan to attempt suicide in near future;
  • Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse; Axis II diagnosis of antisocial personality (by SCID-P and DSM-IV);
  • History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are exclusion criteria);
  • Dementia: Mattis Dementia Rating Scale scores below 130 or diagnosis of dementia by DSM-IV; multiple sclerosis, history of head trauma or history of electroconvulsive therapy;
  • Amnestic Mild Cognitive Impairment (a-MCI), or Multiple Domain Mild Cognitive Impairment (md-MCI);
  • Acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal;
  • Presence of a neurological brain disease and/or history of electroconvulsive therapy;
  • Current involvement in psychotherapy;
  • Inability to perform any of the ADLs (MAI: ADL subscale) even with assistance, e.g. walking with a cane is not an exclusion criterion;

Outcomes

Primary Outcomes

Montgomery-Asberg Depression Rating Scale

Time Frame: 4-6 weeks

10 item measure to assess the core symptoms and cognitive features of clinical depression

Study Sites (1)

Loading locations...

Similar Trials